ELLEGAARD GOTTINGEN MINIPIGS AS

Their core work

Ellegaard Göttingen Minipigs is a Danish private company and the world's leading commercial breeder of Göttingen Minipigs — a standardized miniature pig line developed specifically for biomedical and preclinical research. Their animals serve as in vivo models in pharmaceutical and toxicological studies due to the pig's close physiological and anatomical resemblance to humans, particularly in cardiovascular, metabolic, and reproductive systems. In H2020 research, they contribute as an animal model provider enabling translational studies: their minipigs supported liver biomarker validation in LITMUS and preclinical reproductive safety work in ConcePTION. For research consortia requiring a regulated, reproducible, and commercially available large-animal model that bridges cell studies and human trials, they are effectively the go-to European source.

What they specialise in

How they've shifted over time

Their earliest H2020 involvement centered on liver disease — specifically NAFLD biomarker discovery in the LITMUS project, where a metabolically characterized minipig model is a natural fit. By 2019 their focus extended to pregnancy pharmacovigilance and drug safety monitoring, reflecting a shift from metabolic disease models toward reproductive and developmental safety applications. This trajectory suggests they are deliberately broadening the therapeutic areas in which their minipig platform is validated, moving from a single-disease supplier toward a multi-indication preclinical model provider.

They appear to be systematically validating their minipig model across additional therapeutic areas — from metabolic liver disease toward reproductive toxicology — which signals growing relevance for any consortium needing large-animal in vivo data in drug safety or women's health research.

How they like to work

Ellegaard participates exclusively as a consortium partner and has never led an H2020 project, which is consistent with a specialized supplier whose value is access to a unique biological resource rather than research coordination. Their 115 unique partners across 26 countries from just two projects indicates they join very large, multi-institutional RIA consortia where their minipig models serve multiple research teams simultaneously. This makes them a reliable, low-friction partner — they bring a defined, reproducible contribution and do not compete with academic or clinical partners for leadership roles.

Despite only two H2020 projects, they have worked with 115 unique partners across 26 countries — a footprint that reflects the scale of LITMUS and ConcePTION, both being large pan-European research infrastructures. No single geographic cluster dominates, consistent with their role as a pan-European supplier serving research groups wherever they are based.

What sets them apart

Ellegaard occupies a near-monopoly position in Europe as a commercial-scale supplier of characterized, pathogen-free Göttingen Minipigs — a resource that cannot be replicated quickly by a university or research institute. Regulatory bodies and pharmaceutical companies accept the Göttingen Minipig as a standard non-rodent model, which means their involvement in a consortium can directly support a project's path toward clinical translation or regulatory submission. For consortium builders needing a large-animal in vivo partner with consistent genetics, documented health status, and commercial reliability, there is simply no comparable alternative in the EU.

Highlights from their portfolio

• LITMUS
  A flagship European multi-center study validating non-invasive biomarkers for NAFLD/NASH — one of the most prevalent liver diseases globally — where Ellegaard's minipig models provided translatable in vivo disease representation across a seven-year study window.
• ConcePTION
  A large ecosystem project building infrastructure for drug safety monitoring in pregnancy, demonstrating Ellegaard's expanding role beyond metabolic disease into reproductive pharmacology and real-world evidence generation.